SG10202012842SA - Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome - Google Patents
Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndromeInfo
- Publication number
- SG10202012842SA SG10202012842SA SG10202012842SA SG10202012842SA SG10202012842SA SG 10202012842S A SG10202012842S A SG 10202012842SA SG 10202012842S A SG10202012842S A SG 10202012842SA SG 10202012842S A SG10202012842S A SG 10202012842SA SG 10202012842S A SG10202012842S A SG 10202012842SA
- Authority
- SG
- Singapore
- Prior art keywords
- syndrome
- treatment
- attention deficit
- glutamate receptor
- metabotropic glutamate
- Prior art date
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215636P | 2015-09-08 | 2015-09-08 | |
| US201562215673P | 2015-09-08 | 2015-09-08 | |
| US201562215628P | 2015-09-08 | 2015-09-08 | |
| US201562215633P | 2015-09-08 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202012842SA true SG10202012842SA (en) | 2021-01-28 |
Family
ID=56943962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012842SA SG10202012842SA (en) | 2015-09-08 | 2016-09-07 | Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome |
Country Status (12)
| Country | Link |
|---|---|
| US (12) | US9884057B2 (ja) |
| EP (9) | EP3964213B1 (ja) |
| JP (8) | JP7281280B2 (ja) |
| CN (7) | CN108495630A (ja) |
| AU (8) | AU2016318775B2 (ja) |
| CA (5) | CA2997189A1 (ja) |
| DK (4) | DK3347015T3 (ja) |
| ES (4) | ES2909329T3 (ja) |
| HK (4) | HK1258446A1 (ja) |
| IL (10) | IL300474A (ja) |
| SG (1) | SG10202012842SA (ja) |
| WO (4) | WO2017044503A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2686300T3 (es) | 2010-08-24 | 2018-10-17 | The Children's Hospital Of Philadelphia | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo |
| CN108495630A (zh) | 2015-09-08 | 2018-09-04 | 费城儿童医院 | 诊断和治疗图雷特多综合征的方法 |
| WO2017210502A1 (en) * | 2016-06-03 | 2017-12-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| US10918632B2 (en) * | 2016-09-07 | 2021-02-16 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
| US11684617B2 (en) | 2017-04-19 | 2023-06-27 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating ADHD in biomarker positive subjects |
| WO2018209328A1 (en) * | 2017-05-11 | 2018-11-15 | Miwa Julie M | Compositions and methods for treating lynx2 disorders |
| CN107483425B (zh) * | 2017-08-08 | 2020-12-18 | 北京盛华安信息技术有限公司 | 基于攻击链的复合攻击检测方法 |
| US11535604B2 (en) | 2018-01-18 | 2022-12-27 | The Children's Hospital Of Philadelphia | Fasoracetam crystalline forms |
| KR20200130250A (ko) * | 2018-01-18 | 2020-11-18 | 더 칠드런스 호스피탈 오브 필라델피아 | 파소라세탐의 고체 형태 |
| KR102250063B1 (ko) * | 2019-06-14 | 2021-05-12 | 한국생명공학연구원 | 뚜렛증후군의 원인 유전자를 동정하는 방법 |
| CN110955751A (zh) * | 2019-11-13 | 2020-04-03 | 广州供电局有限公司 | 工作票文本去重方法、装置、系统及计算机存储介质 |
| JP2023543439A (ja) * | 2020-09-21 | 2023-10-16 | リベラジェン・バイオファーマ・インコーポレイテッド | ＮＦ－κＢ媒介疾患の処置 |
| WO2022065518A1 (ja) * | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | 神経突起伸長促進剤 |
| CN117594119B (zh) * | 2024-01-17 | 2024-05-10 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002245486B2 (en) * | 2001-02-23 | 2006-11-16 | Ucb Pharma, S.A. | Treatment of tics, tremors and related disorders |
| CA2471198A1 (en) | 2001-12-20 | 2003-07-03 | Merck & Co., Inc. | Identification of novel polymorphic sites in the human mglur8 gene and uses thereof |
| WO2005094801A1 (en) | 2004-03-25 | 2005-10-13 | Smithkline Beecham Corporation | Use of an nk3 antagonist for the treatment of bipolar disorders |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007104035A1 (en) | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200819458A (en) | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| CA2676090A1 (en) | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| WO2008136988A2 (en) | 2007-04-30 | 2008-11-13 | The Ohio State University Research Foundation | Polymorphisms in genes affecting cyp2c9-related disorders and uses thereof |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| AU2009217278B2 (en) | 2008-02-20 | 2015-08-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| WO2010057132A1 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same |
| CA2766246C (en) | 2008-11-14 | 2020-03-10 | Hakon Hakonarson | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets |
| US8975286B2 (en) * | 2009-08-20 | 2015-03-10 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| US8714471B2 (en) * | 2010-07-29 | 2014-05-06 | Brady Worldwide, Inc. | Friction core brake |
| ES2686300T3 (es) | 2010-08-24 | 2018-10-17 | The Children's Hospital Of Philadelphia | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo |
| US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| WO2016022324A1 (en) | 2014-05-30 | 2016-02-11 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| BR112015003796A2 (pt) * | 2012-08-23 | 2017-07-04 | L Weg Stuart | composição ansiolítica, formulação e método de uso |
| US9346239B2 (en) | 2012-09-26 | 2016-05-24 | Eastman Kodak Company | Method for providing patterns of functional materials |
| WO2014152965A2 (en) | 2013-03-14 | 2014-09-25 | The Children's Hospital Of Philadelphia | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| KR102232583B1 (ko) | 2015-01-08 | 2021-03-26 | 삼성전자주식회사 | 전자장치 및 전자장치의 웹 재현 방법 |
| EP3307913A4 (en) | 2015-06-15 | 2019-03-27 | The Children's Hospital of Philadelphia | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM |
| CN108495630A (zh) | 2015-09-08 | 2018-09-04 | 费城儿童医院 | 诊断和治疗图雷特多综合征的方法 |
-
2016
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/zh active Pending
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/ja active Active
- 2016-09-07 CA CA2997189A patent/CA2997189A1/en active Pending
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/da active
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/zh active Pending
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 IL IL300474A patent/IL300474A/en unknown
- 2016-09-07 IL IL303605A patent/IL303605A/en unknown
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/zh active Pending
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/ja active Active
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/zh active Active
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/zh active Pending
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/ja active Active
- 2016-09-07 CA CA2997188A patent/CA2997188A1/en active Pending
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 EP EP22156141.8A patent/EP4023222A1/en active Pending
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/da active
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/zh active Pending
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en active Application Filing
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 CA CA2997191A patent/CA2997191A1/en active Pending
- 2016-09-07 ES ES16767112T patent/ES2909329T3/es active Active
- 2016-09-07 ES ES16767115T patent/ES2898932T3/es active Active
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en active Application Filing
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en active Application Filing
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/da active
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 ES ES16767114T patent/ES2897953T3/es active Active
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/da active
- 2016-09-07 ES ES16771034T patent/ES2876898T3/es active Active
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/ja active Active
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en active Application Filing
- 2016-09-07 EP EP24153857.8A patent/EP4342493A2/en active Pending
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/zh active Pending
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
-
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
-
2018
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
-
2019
- 2019-01-16 HK HK19100751.8A patent/HK1258446A1/zh unknown
- 2019-01-16 HK HK19100753.6A patent/HK1258448A1/zh unknown
- 2019-01-16 HK HK19100752.7A patent/HK1258447A1/zh unknown
- 2019-01-16 HK HK19100745.7A patent/HK1258373A1/zh unknown
-
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US20210205288A1/en active Pending
-
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
-
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/ja active Pending
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-02-28 IL IL290985A patent/IL290985A/en unknown
- 2022-02-28 IL IL290994A patent/IL290994A/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en active Pending
- 2022-05-05 AU AU2022203039A patent/AU2022203039A1/en active Pending
- 2022-06-20 AU AU2022204324A patent/AU2022204324A1/en active Pending
- 2022-06-21 AU AU2022204355A patent/AU2022204355A1/en active Pending
- 2022-07-11 AU AU2022205142A patent/AU2022205142A1/en active Pending
- 2022-09-29 JP JP2022155714A patent/JP2023011558A/ja active Pending
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/ja active Pending
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/ja active Pending
-
2023
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290992A (en) | Non-selective metabotropic glutamate receptor activators for the treatment of ADHD and 22q syndrome | |
| IL250436B (en) | Medical pad systems and methods | |
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| GB2537970B (en) | Shade adjustment notification system and method | |
| IL248757B2 (en) | Controllable drug delivery system and method of use | |
| GB201802952D0 (en) | Itinerary generation and adjustment system | |
| HK1215119A1 (zh) | 治療產品遞送系統和配對方法 | |
| HK1212791A1 (zh) | 可動態組合和調整的個人工作系統 | |
| HUE052709T2 (hu) | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására | |
| HK1244429A1 (zh) | 特別用於治療注意力缺陷障礙的方法和組合物 | |
| HK1232182A1 (zh) | 用於產生火焰效果的系統和方法 | |
| DK3113782T3 (da) | Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin | |
| IL267205A (en) | Inhibited waxy starches and methods of using them | |
| IL251387B (en) | Sphingosine-1-phosphate receptor modulators for the treatment of cardiopulmonary disorders | |
| FI20146023A (fi) | Hammas- ja kielituki | |
| HK1259078A1 (zh) | 合成的鞘脂類分子、藥物、它們的合成方法及治療方法 | |
| PL3000407T3 (pl) | Urządzenia i sposoby do stabilizacji elementów mocujących po rozmieszczeniu | |
| IL249894A0 (en) | Targeted medical nanoparticles and methods for their preparation and use | |
| IL255420A0 (en) | Selective modulators of gpr55 receptor activity: chromopyrazole derivatives | |
| PL3288483T3 (pl) | System kotwienia i pozycjonowania czaszkowego | |
| IL264165A (en) | Inhibited starches, coagulation retarders and methods of using them | |
| GB201411150D0 (en) | Novel aptamers and therapeutic uses thereof | |
| GB2531711B (en) | Authentication system and method of authentication | |
| GB201615010D0 (en) | Delayed-gelling, inhibited starches and methods of using them | |
| GB2529144B (en) | Adjustable track system and method of configuring same |